

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>( Not for submission under 37 CFR 1.99)</i>	Application Number	10583996
	Filing Date	2007-06-11
	First Named Inventor	Yechici SHAI
	Art Unit	1654
	Examiner Name	Ronald T. Niebauer
	Attorney Docket Number	SHAI 8

U.S.PATENTS						
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	5464933		1995-11-07	BOLOGNESI et al	
	2	5840843		1998-11-24	JIANG et al	
	3	6013263		2000-01-11	BARNEY et al	
	4	6017536		2008-09-05	BARNEY et al	
	5	6020459		2000-02-01	BARNEY et al	
	6	6093794		2000-07-25	BARNEY et al	
	7	6133413		2000-10-17	MOURI et al BOLOGNESI et al	
	8	6133418		2000-10-17	BOLOGNESI et al	

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10583996
Filing Date	2007-06-11
First Named Inventor	Yechici SHAI
Art Unit	1654
Examiner Name	Ronald T. Niebauer
Attorney Docket Number	SHAI 8

9	6228983	2001-05-08	BARNEY et al
10	6518013	2003-02-11	BARNEY et al

If you wish to add additional U.S. Patent citation information please click the Add button.

**U.S.PATENT APPLICATION PUBLICATIONS**

Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button.

**FOREIGN PATENT DOCUMENTS**

Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup>	Kind Code <sup>4</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T <sup>5</sup>
	1	9428920	WO	A1	2008-09-05	DUKE UNIVERSITY		<input type="checkbox"/>
	2	9640191	WO	A1	1996-12-19	TRIMERIS INC.		<input type="checkbox"/>
	3	03023013	WO	A2	2003-03-20	HYSEQ INC.		<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

**NON-PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>5</sup>
--------------------	---------	---	----------------

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10583996
Filing Date	2007-06-11
First Named Inventor	Yechici SHAI
Art Unit	1654
Examiner Name	Ronald T. Niebauer
Attorney Docket Number	SHAI 8

1	Eckert D. M. et al., "Inhibiting HIV-1 entry: discovery of D-peptide inhibitors that target the gp41 coiled-coil pocket". Cell 1999;99:103-115.	<input type="checkbox"/>
2	Gerber D. et al., "Insertion and organization within membranes of the delta-endotoxin pore-forming domain, helix 4-loop-helix 5, and inhibition of its activity by a mutant helix 4 peptide". J Biol Chem. 2000 Aug 4;275(31):23602-7.	<input type="checkbox"/>
3	Gerber D. et al., "In vivo detection of hetero-association of glycophorin-A and its mutants within the membrane". J Biol Chem. 2001 Aug 17;276(33):31229-32.	<input type="checkbox"/>
4	Gerber D. et al., "Chirality-independent protein-protein recognition between transmembrane domains in vivo". J Mol Biol. 2002 Sep 20;322(3):491-5.	<input type="checkbox"/>
5	Judice J.K. et al., "Inhibition of HIV type 1 infectivity by constrained alpha-helical peptides: implications for the viral fusion mechanism". Proc Natl Acad Sci U S A. 1997 Dec 9;94(25):13426-30.	<input type="checkbox"/>
6	Kliger Y. et al., "Mode of action of an antiviral peptide from HIV-1. Inhibition at a post-lipid mixing stage". J Biol Chem. 2001 Jan 12;276(2):1391-7.	<input type="checkbox"/>
7	Kliger Y. et al., "Fusion peptides derived from the HIV type 1 glycoprotein 41 associate within phospholipid membranes and inhibit cell-cell Fusion. Structure-function study". J Biol Chem. 1997 May 23;272(21):13496-505.	<input type="checkbox"/>
8	Lu M. et al., "A trimeric structural subdomain of the HIV-1 transmembrane glycoprotein". J Biomol Struct Dyn. 1997 Dec;15(3):465-71.	<input type="checkbox"/>
9	Mackenzie K. et al., "A transmembrane helix dimer: structure and implications". Science 1997;276: 131-133.	<input type="checkbox"/>
10	Manolios N. et al., "T-cell antigen receptor transmembrane peptides modulate T-cell function and T cell-mediated disease". Nat. Med. 1997;3:84-88.	<input type="checkbox"/>
11	Melnik Roman A. et al., "Retention of native-like oligomerization states in transmembrane segment peptides: Application to the Escherichia coli aspartate receptor". BIOCHEMISTRY, vol. 40, no. 37, 2001, 11106-11113.	<input type="checkbox"/>

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10583996
Filing Date	2007-06-11
First Named Inventor	Yechici SHAI
Art Unit	1654
Examiner Name	Ronald T. Niebauer
Attorney Docket Number	SHAI 8

12	Pritsker M. et al., "A synthetic all D-amino acid peptide corresponding to the N-terminal sequence of HIV-1 gp41 recognizes the wild-type fusion peptide in the membrane and inhibits HIV-1 envelope glycoprotein-mediated cell fusion". Proc Natl Acad Sci U S A. 1998 Jun 23;95(13):7287-92.	<input type="checkbox"/>
13	Rutledge T. et al., "Transmembrane helical interactions: zeta chain dimerization and functional association with the T cell antigen receptor". Embo J. 1992;11:3245-3254.	<input type="checkbox"/>
14	Russ W. P. et al., "The GxxxG motif: a framework for transmembrane helix-helix association". J. Mol. Biol. 2000;296: 911-919.	<input type="checkbox"/>
15	Sal-Man N. et al., "Hetero-assembly Between All-I- and All-d-Amino Acid Transmembrane Domains: Forces Involved and Implication for Inactivation of Membrane Proteins". JOURNAL OF MOLECULAR BIOLOGY, LONDON, GB, vol. 344, no. 3, 2004, 855-864.	<input type="checkbox"/>
16	Shai Y. et al., "Diastereoisomers of cytolsins, a novel class of potent antibacterial peptides". J. Biol. Chem. 1996;271:7305-7308.	<input type="checkbox"/>
17	Shai Y. et al., "From "carpet" mechanism to de-novo designed diastereomeric cell-selective antimicrobial peptides". PEPTIDES (NEW YORK), vol. 22, no. 10, 2001, 1629-2641.	<input type="checkbox"/>
18	Wild C. et al., "A synthetic peptide from HIV-1 gp41 is a potent inhibitor of virus-mediated cell-cell fusion". AIDS Res Hum Retroviruses. 1993 Nov;9(11):1051-3.	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

**EXAMINER SIGNATURE**

Examiner Signature	/Ronald Niebauer/	Date Considered	04/06/2009
--------------------	-------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> See Kind Codes of USPTO Patent Documents at [www.USPTO.GOV](http://www.USPTO.GOV) or MPEP 901.04. <sup>2</sup> Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>3</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>4</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>5</sup> Applicant is to place a check mark here if English language translation is attached.